Skip to content
  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
Daily News India

Daily News India

Just another WordPress site

  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Toggle search form
  • Interior Company by Square Yards Redefines the Post-Possession Journey with Tech-driven Interior Solutions Business
  • Coveted “Lifetime Achievement Award 2023” conferred on OSL Founder Mahimananda Mishra Business
  • Sushil Sharma Strengthens National and Community Leadership with Roles at BRICS CCI, ESC and Rotary Lifestyle
  • PolkaTots.in – A Trusted Name in Baby Products Business
  • Tunwal E-Motors Limited (NSE SYMBOL: TUNWAL) Achieves 75% Revenue Growth in FY 25 to Rs.184.86 Cr Business
  • Evexia’s move of acquiring Revin labs, Robust growth forecasted Finance
  • LIBERTY announced its Q2 and H1 ended 30th September, 2022 Unaudited Financial Results Business
  • Under Covid Crisis, Crypto shows Its True Value C

ISSAR Pharma Announces Out-Licensing of Its Peptide-Based NCEs

Posted on April 29, 2021 By

ISSAR Pharma, the only company in India which focuses on the research and development of New Chemical Entities (NCE), is licensing out its NCEs based on peptide technology, opening opportunities for fruitful partnerships.

Hyderabad (Telangana) [India], April 29: ISSAR Pharmaceuticals, the Pioneer in Peptide Technology and peptide drug innovation, has decided to license out their peptide-based New Chemical Entities (NCEs), with pre-IND filing and US Patent. The potential collaboration would help ISSAR Pharmaceuticals in their goal to design and deliver novel peptide-based drugs for various unmet healthcare needs of the population and making them affordable and accessible for better health outcomes.

ISSAR Pharmaceuticals exclusively focuses on peptide technology-based research and development of New Chemical Entities (NCE) for various unmet medical needs to improve the quality of life. ISSAR uses Solid-phase peptide synthesis as the technology of choice and has the capability to synthesize custom peptides, API peptides, and cosmetic peptides at all scales within a short duration. With an emphasis on quality, safety, and innovation, ISSAR has demonstrated the ability to move products from conceptualisation to commercialisation of peptide molecules at all stages. ISSAR has several patents for potential life-changing peptide molecules lined up in their development pipeline targeting therapeutic areas such as oncology, dermatology, gastroenterology, and diseases of bones and joints.

“We take pride in being India’s first-ever company to conduct phase-1 clinical trials and launch the first-ever indigenous peptide drug, Melgain in the market for the treatment of Vitiligo in 2004”, informs Mr. Ramakrishna Reddy Isanaka, the founder of ISSAR. ISSAR’s

FDA- compliant state-of-the-art manufacturing facility of 62000 sq. ft., is purely into peptide manufacturing technology, located in Genome Valley, Hyderabad, India. In addition to its experience in R&D, ISSAR is equipped with the most advanced and automatic technology with expertise in the synthesis and purification of peptides, producing the highest standards of purity of up to 99.5% by continued process optimization.

With over 25 years of experience and a prime focus in Research and Development, ISSAR’s dedicated team of experts is proud to have developed India’s first-ever peptide molecule, Melgain for the treatment of Vitiligo in 2004, which is now introduced as Novoskin® with improved properties and effectiveness. ISSAR’s commitment has also led to the development of their second New Chemical Entity called Xylentra, which is the first-ever peptide drug in the world for the treatment of burn wounds and microbial infections.

ISSAR developed molecules for prevalent conditions in the Western world such as Inflammatory Bowel Diseases (IBD), Psoriasis, and Sepsis. Recently, an NCE for the treatment of burn wounds (Xylentra) was licensed to Viatris, formerly known as Mylan Laboratories, the USA in 2020.

ISSAR Pharmaceuticals was founded by Mr. Ramakrishna Reddy Isanaka in 1995 with a vision to be a global leader in peptide drug discovery for improving patients’ quality of life. Before starting ISSAR Pharmaceutical, Mr.Isanaka was the promoter and director of Shantha Biotechnics in the 1980s, at a time when Biotechnology was new to India.

His efforts in research and development led to the advancement of ISSAR Pharma as the first-ever company in India to conduct Phase-I Clinical Trials in the year 1995. Today, he has over 25 years of experience in the development of NCEs with 2 successfully commercialized products, 7 plus patents to his credit, and over 6 commercially viable products under development.

https://issar.co.in/

English, Health, Press Release Tags:ISSARPharma, PeptidebasedNCEs, PNN

Post navigation

Previous Post: Glimpse up the world @worldwithmaria
Next Post: Indian Furniture Rental Industry – Market Size, Growth & Scope

Related Posts

  • IACC x 360One Presents 3rd Edition of Open Golf Tournament 2025 Press Release
  • Kranti Shanbhag owns South Africa Legends franchise in Road Safety World Series Season 2 Press Release
  • Amit Pathak, quietly ushering in a new revolution in mental health care English
  • Wanhai Medical: Leading the Market with High-Quality Injection Pens Health
  • Hair gone, Regrown again – A homeopathic way to regain hair after Chemotherapy Health
  • Dr. BK Deepak Harke awarded “Bharat Gaurav Sanman” by Corporate Life Coach Dr. Mickey Mehtain Zurich Switzerland Press Release

Recent Posts

  • IBMA Organises First-Ever Indian Lead Battery Conference 2026 in Goa
  • Why Creator-Gear is a B2B Business now: agencies, schools, and production houses?
  • Prateek Group Brings The New Era of Luxury Real Estate
  • Top Bathroom Tile Brands in India: Wall, Floor and Anti-Skid Options Compared
  • Parul University moves to 401-500 band in Times Higher Education (THE) Interdisciplinary Science Rankings 2027

Recent Comments

  • Unknown on Participants Reap Rewards in Wellman’s 8-Week Digital Campaign: IPL Tickets, Autographed Virat Kohli Merchandise, and More!
  • Book Review of ‘The Waiting Lounge’ by Chet Kamal Parkash Lifestyle
  • Surat Celebrity Box Cricket League Season 4: A Mega Platform Uniting Influencers and Brands Nationwide for Collaborative Success Lifestyle
  • Augmented Reality Training at IPS Academy’s Institute of Fashion Technology Education
  • Indigo Global School – A new era of schooling Press Release
  • Alan Fenandes – one of the most sought-after coaches in the world of Mixed Martial Arts. English
  • “Boring Makes Money, Belief Makes Freedom”: Siddharth Kannan Hosts Vishal B Malkan and Meghana V Malkan in a Candid Wealth Reality Check Entertainment
  • Gold Imports, Forex Reserves, and India’s Balancing Act Finance
  • Regulatory Review Draws Attention to Online Forex Trading Ecosystem Finance

Copyright © 2026 Daily News India.

Powered by PressBook News WordPress theme